Biochemical and Biophysical Research Communications
Functional cloning of Vibrio parahaemolyticus type III secretion system 1 in Escherichia coli K-12 strain as a molecular syringe
Highlights
► We cloned functional Vibrio parahaemolytics T3SS1 in E. coli K-12. ► Cloned Vp T3SS1 in Escherichia coli K-12 injects foreign proteins into host cells. ► Cloned Vp T3SS1 has potential to be used in experimental and therapeutic application.
Introduction
Targeting bioactive molecules to specific human cells or organs is quite fascinating in many ways [1]. Vaccine development, anti-cancer therapy and other clinical treatments are all amenable to such systems. Various targeting systems have been developed. However, no perfect systems exist that are applicable to all conditions, and the development of novel technology has been anticipated. One of the potential systems for this purpose is a bacterial type III secretion system (T3SS) [2]. The T3SS is composed of the sophisticated protein translocation machinery found in gram-negative bacteria that allows them to inject virulence factors, or so-called ‘effectors’, directly into host cells. The T3SS thus contributes substantially to the establishment of a bacterial niche in the host. The details of the protein secretion mechanism and structures have been extensively studied, and at present, the minimal components required to establish the functional T3SS are known. The T3SS consists of two components: the needle and the basal body. The needle is the conduit for proteins secreted from the inside to the outside of the bacteria, whereas the basal body is the platform required to prepare the proteins for the secretion [3]. The establishment of this complicated system requires the expression of more than 20 genes. However, successful functional cloning of this useful tool, especially in non-pathogenic bacteria, is beneficial for many researchers seeking to develop novel clinical and basic application strategies in areas such as vaccine administration, the development of a screening system for anti-T3SS drugs and the target-specific delivery of bioactive compounds [4], [5], [6]. In this study, we successfully constructed the cloned Vibrio parahaemolyticus T3SS1 genetic locus into a non-pathogenic E. coli K-12 strain. A translocation assay revealed that the cloned T3SS had the ability to inject foreign proteins tagged with the region essential for secretion of the T3SS1 effector, VepA, as well as that of the proteins secreted by V. parahaemolyticus T3SS1, providing a prospective molecular syringe.
Section snippets
Bacterial strains and growth conditions
V. parahaemolyticus RIMD2210633 [7] and its derivative strains were employed as genomic DNA sources of the T3SS1-related gene-coding region (Fig. 1) [8], [9]. A non-pathogenic E. coli K12 derivative strain, VCS257 (Agilent Technologies, Santa Clara, CA) was used for the cosmid transduction and as a host strain of the cloned T3SS. Bacterial cultures were grown at 37 °C in 3% LB medium (1% bacto tryptone, 0.5% yeast extract, 3% NaCl) for V. parahaemolyticus and LB medium (1% bacto tryptone, 0.5%
Cloning of the T3SS1 genetic locus of V. parahaemolyticus
To construct non-pathogenic E. coli expressing T3SS, there are many candidates as a source for T3SS genetic locus. This locus can be constructed using any T3SS from a variety of pathogenic bacteria. However, the locus should be harmless and have no adverse effects in target cells when this molecular syringe is employed as a tool. From this point of view, the T3SS genetic locus must at the minimum establish a protein secretory apparatus. Our previous studies revealed that the genome of
Discussion
T3SS is a sophisticated system to deliver proteins directly into host cells. A number of studies about T3SS have been reported over the recent couple of decades [19]. T3SS has been found in pathogenic bacteria and has been utilized to establish a niche of infection in host cells. This approach implies that much potential exists for the usage of T3SS as a molecular tool. Previous studies have shown some promising results for the establishment of a “molecular syringe” [20], [21], [22], [23].
Acknowledgments
This work was supported by Grants-in-Aid for Young Scientists and Scientific Research in Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan and from the Takeda Science Foundation. The plasmid pCX340 was generously provided by Dr. Eric Oswald of the Institut National de la Recherche Agronomique, Ecole Nationale Veterinaire de Toulouse, France.
References (23)
- et al.
Delivery of bioactive molecules into the cell: the Trojan horse approach
Molecular and Cellular Neuroscience
(2004) - et al.
Biogenesis, regulation, and targeting of the type III secretion system
Structure
(2011) - et al.
Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors
International journal of medical microbiology: IJMM
(2008) - et al.
Genome sequence of Vibrio parahaemolyticus: a pathogenic mechanism distinct from that of V cholerae
Lancet
(2003) - et al.
Cloning of a functional Salmonella SPI-1 type III secretion system and development of a method to create mutations and epitope fusions in the cloned genes
Journal of biotechnology
(2006) - et al.
Protein delivery into eukaryotic cells by type III secretion machines
Nature
(2006) - et al.
A recombinant attenuated Salmonella enterica serovar Typhimurium vaccine encoding Eimeria acervulina antigen offers protection against E. acervulina challenge
Infection and immunity
(2006) Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: potential application in vaccine and therapeutical developments
Immunopharmacology and immunotoxicology
(2010)- et al.
Functional characterization of two type III secretion systems of Vibrio parahaemolyticus
Infection and immunity
(2004) - et al.
Identification of proteins secreted via Vibrio parahaemolyticus type III secretion system 1
Infection and immunity
(2006)
Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter
Journal of bacteriology
Cited by (9)
Rationale redesign of type III secretion systems: toward the development of non-pathogenic E. coli for in vivo delivery of therapeutic payloads
2018, Current Opinion in MicrobiologyCitation Excerpt :T4SSs will need to be extensively modified to optimize DNA transfer before they are ready for therapeutic development; however, given that they transfer DNA via a conjugative-like process, which does not discriminate between DNA length or sequence, the potential clinical applications for these systems are quite broad. While the T3SSs of both Vibrio parahaemolyticus and Yersinia pestis have been demonstrated to be functional when transferred into laboratory strains of E. coli [34,35], a major advance in the use of T3SSs as therapeutic vectors is the recent development of non-pathogenic strains of E. coli that express a functional, programmable T3SS [36••,37••]. Like KBMA Pseudomonas and ΔminD Salmonella-derived minicells, these bacteria are completely avirulent.
Transfer of the cloned Salmonella SPI-1 type III secretion system and characterization of its expression mechanisms in Gram negative bacteria in comparison with cloned SPI-2
2015, Microbiological ResearchCitation Excerpt :Bacterial protein secretion systems can be cloned on large contiguous DNA segments, transferred to other bacterial strains, and used for the study and application of the particular system for bacterial engineering purposes (Karaolis et al. 1997; McDaniel and Kaper 1997; Hansen-Wester et al. 2004; Wilson and Nickerson 2006a; Wilson et al. 2007; Blondel et al. 2010; Akeda et al. 2012; Bao et al. 2012). In addition, important information about the evolution of the cloned system can be obtained when its expression and functional activity is studied outside of its original genomic context in bacteria other than the species of origin (Hansen-Wester et al. 2004; Wilson et al. 2004; Wilson and Nickerson 2006a,b; Wilson et al. 2007; Akeda et al. 2012; Bao et al. 2012). Cloned type III secretion systems (T3SS) have much potential for bacterial engineering applications involving vaccine delivery, anti-cancer strategies, and other specifically-designed bacterial-eukaryotic cell interactions (Panthel et al. 2008; Xiong et al. 2010; Carleton et al. 2013; Xu et al. 2014).
Engineering large functional plasmids for biosafety
2013, PlasmidCitation Excerpt :Large bacterial plasmids (generally 25–100 kb, but can be greater) encoding functional gene systems possess significant potential for applications in medical or environmental settings including protein secretion (Akeda et al., 2012; Blondel et al., 2010; Ham et al., 1998; Hansen-Wester et al., 2004; McDaniel and Kaper, 1997; Wilson et al., 2007; Wilson and Nickerson, 2006a), gene delivery (Cheung et al., 2012; Kong et al., 2012; Yamada et al., 2012), bioremediation (Basta et al., 2004; Rodriguez-Herva et al., 2007; Yano et al., 2010), biofilm formation (Jennings et al., 2012), and engineered prokaryotic/eukaryotic interactions (Jamir et al., 2004; McDaniel and Kaper, 1997; Oh et al., 2010).
Intracellular delivery of biologic therapeutics by bacterial secretion systems
2017, Expert Reviews in Molecular MedicineAn Engineered Outer Membrane-Defective Escherichia coli Secreting Protective Antigens against Streptococcus suis via the Twin- Arginine Translocation Pathway as a Vaccine
2022, Journal of Microbiology and Biotechnology